Mirum Pharmaceuticals to Present at Investor Conferences in September
September 11 2020 - 7:00AM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for debilitating liver diseases, today announced that the
company will present at the following virtual investor conferences
in September.
H.C. Wainwright & Co. 22nd Annual Global Investment
Conference September 14-15, 2020 Presentation day and time:
Monday, September 14, 2020 at 9:30am ET
Cantor Fitzgerald Virtual Global Healthcare Conference
September 15-17, 2020 Presentation day and time: Thursday,
September 17, 2020 at 9:20am ET
A live audio webcast and archive of the presentations will be
available in the Investors & Media section of the company
website at ir.mirumpharma.com.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for
debilitating liver diseases. The company’s lead product candidate,
maralixibat, is an investigational oral drug in development for
Alagille syndrome (ALGS), progressive familial intrahepatic
cholestasis (PFIC), and biliary atresia. The company has initiated
a rolling NDA submission for maralixibat in the treatment of
patients with cholestatic pruritus associated with ALGS and expects
to complete the submission in the first quarter of 2021.
Additionally, the company plans to submit a marketing authorization
application to the European Medicines Agency for maralixibat in the
treatment of patients with PFIC2 in the fourth quarter 2020.
The company is also developing volixibat, also an oral
ASBT-inhibitor, in primary sclerosing cholangitis and intrahepatic
cholestasis of pregnancy. For more information,
visit MirumPharma.com.
Follow Mirum on Twitter, Facebook and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200911005100/en/
Investor contact: Ian Clements, Ph.D. ir@mirumpharma.com
Media contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2023 to Apr 2024